In research directly comparing the mutation profiles of cases with endometrioid carcinoma of the ovary and endometrium, loss of expression in ARID1A, PTEN, and MSI-H is more commonly observed in the endometrium than in the ovary, while CTNNB1 mutation is statistically more prevalent in the ovary than in the endometrium17. This evidence concerns the gene ARID1A and ovarian endometrioid adenocarcinoma.